Nipocalimab is an investigational IgG1 monoclonal antibody developed by Momenta Pharmaceuticals that binds to the neonatal Fc receptor (FcRn). It has been granted Orphan Drug Designation by the FDA for the prevention of hemolytic disease of the fetus and newborn (HDFN) and has demonstrated positive results in a Phase 2 clinical trial for the treatment of myasthenia gravis.